Results 121 to 130 of about 19,019 (189)

Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®. [PDF]

Pharmacol Res Perspect
Saint-Lary L, Lacroix I, Leroy V, Sommet A.   +3 more
europepmc   +1 more source

Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602. [PDF]

J Virol, 2022
Ohata Y, Tomonaga M, Watanabe Y, Tomura K, Kimura K, Akaki T, Adachi K, Kodama EN, Matsuzaki Y, Hayashi H.   +9 more
europepmc   +1 more source

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial [PDF]

, 2010
Andrew Zolopa, Daniel S Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey Enejosa, Brian P. Kearney, Andrew Cheng   +7 more
openalex   +1 more source

Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens. [PDF]

Front Immunol
Funderburg NT, Huang SSY, Cohen C, Ailstock K, Cummings M, Lee JC, Ng B, White K, Wallin JJ, Downie B, McComsey GA.   +10 more
europepmc   +1 more source

HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H. [PDF]

J Antimicrob Chemother, 2022
Aulicino PC, Momin Z, Rozenszajn M, Monzon A, Arazi-Caillaud S, Bologna R, Mangano A, Kimata JT.   +7 more
europepmc   +1 more source

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961) [PDF]

, 2010
Joseph J. Eron, JM Livrozet, Philippe Morlat, Adriano Lazzarin, Christine Katlama, Trevor Hawkins, Tamio Fujiwara, Robert L. Cuffe, Cindy Vavro, Julio Montes Santiago, Mounir Ait‐Khaled, Sherene Min, JM Yeo   +12 more
openalex   +1 more source

Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy. [PDF]

Drugs Context
Januszka J, Drwiega E, Burgos R, Smith R, Badowski M.   +4 more
europepmc   +1 more source

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. [PDF]

J Acquir Immune Defic Syndr, 2022
D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL.   +6 more
europepmc   +1 more source

Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor. [PDF]

Virol J, 2021
Park KH, Kim M, Bae SE, Lee HJ, Kim KC, Choi BS, Kim YB.   +6 more
europepmc   +1 more source

Glycemic Control in Patients Living With HIV Initiated on Integrase Inhibitor-Based Three-Drug Antiretroviral Therapy. [PDF]

J Pharm Technol
Gerber A, Fischetti B, Popova O, Longo M.   +3 more
europepmc   +1 more source